The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1555
Roxybond - An Abuse-Deterrent Formulation of Immediate-Release Oxycodone
The full article is available to subscribers Subscriber Login   

The FDA has approved Roxybond (Daiichi Sankyo), an immediate-release (IR) oxycodone formulation with abuse-deterrent properties, for treatment of pain requiring management with an opioid. Roxybond is the first IR opioid to be approved as an abuse-deterrent product. Oxaydo, another IR oxycodone formulation, has properties that discourage its intranasal and intravenous use, but is not considered an abuse-deterrent product by the FDA. Use of opioids for treatment of pain was reviewed in a recent issue.1

ABUSE-DETERRENT OPIOIDS — Abuse-deterrent opioid formulations have properties that make their intentional nontherapeutic use more difficult, less attractive, and less rewarding, but they are expensive, and whether they reduce overall opioid abuse remains to be determined. No oral opioid formulation prevents consumption of intact dosage units. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Roxybond - An Abuse-Deterrent Formulation of Immediate-Release Oxycodone
Article code: 1555a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian